The Alliance for Clinical Trials in Oncology today announced detailed results will be presented at ESMO 2023 from CABINET (A021602), ...
Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with ...
BOSTON – Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for ...
“Several ongoing trials hope to further elucidate the role of lurbinectedin in highgrade neuroendocrine neoplasms ” Credit: 2023 Bhamidipati and ...
Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target ...
“We recently unveiled a new interesting role for SASP: its ability to induce neuroendocrine transdifferentiation (NED) in breast cancer epithelial ...
Neuroendocrine neoplasms (NENs) are rare cancers that develop from specialized secretory cells of the neuroendocrine system. These cells are found ...
Reston, VA—A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) ...
MIAMI, FLORIDA (March 16, 2023) – Aman Chauhan, M.D., and Sylvester Comprehensive Cancer Center at the University of Miami Miller ...
PLYMOUTH MEETING, PA — New research from cancer research and treatment organization City of Hope in the December 2022 issue ...
LOS ANGELES — A new study by researchers at City of Hope, one of the largest cancer research and treatment ...
Reston, VA—A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness ...
“The current work provides potentially actionable information that could help to limit premature or accentuated aging in the context of ...
Vancouver, British Columbia, Canada—A targeted radionuclide alpha therapy, 225Ac-DOTATATE, has been shown to have long-term anti-tumor effects in patients with ...
Background:Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective tumor response. Retrospective and small, prospective ...
New Haven, Conn. — Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers ...
LEXINGTON, Ky. (March 29, 2022) — The University of Kentucky Markey Cancer Center Foundation received a $1 million gift to create the world’s ...
Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and ...
Reston, VA—A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of ...
The research group led by Dr. Shojiro Ichimata, and Dr. Yoshiki Sekijima of Shinshu University School of Medicine, Department of ...
